Conart (DIURETICS)

Quick links to important sections

Conart (DIURETICS)

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Conart (DIURETICS)

Property Description
Active ingredient Bumetanide (C17H20N2O5S)
Form Tablets (Oral) and Solution for Injection (Parenteral)
Pharmacological class Loop Diuretic (High-ceiling Diuretic)
General Purpose Management of Fluid Overload and Edema
Origin Synthetic Compound (Sulfonamide derivative)

Conart is a medicinal preparation containing the potent active ingredient Bumetanide, which belongs to the pharmacological class of Diuretics, specifically known as a Loop diuretic. This medicine is classified as a synthetic compound derived from a sulfonamide derivative structure, used to enhance the body's removal of excess fluid and salt.


What Type of Medicine is Conart (DIURETICS)?

Conart is a powerful fluid management agent categorized as a Loop diuretic, distinguishing it from less intensive classes due to its high efficacy and targeted site of action in the kidney. It is often referred to as a high-ceiling diuretic because it has the capacity to produce a significant and rapid increase in urine output (diuresis). As a Loop Diuretic, this medicine is designed to aggressively promote the loss of water and salts. This potency is clinically recognized for providing rapid and substantial fluid mobilization in patients requiring urgent relief. The medicine functions to actively facilitate volume depletion in conditions where the body retains too much fluid.


Composition and Available Drug Forms

The identity of Conart is anchored by its single active ingredient, Bumetanide. This compound is formulated for administration in two primary drug forms: tablets for oral administration and a sterile solution for injection for parenteral administration. The tablet form utilizes standard pharmaceutical excipients, while the injectable solution is prepared in an aqueous-based vehicle. This dual availability allows for flexible use, addressing both acute hospital needs via injection and chronic management through oral tablets. It is designated as a prescription-only medicine, underscoring its potent effects and the need for medical supervision.


What is the General Purpose of Conart?

The general purpose of Conart is to manage abnormal fluid accumulation by significantly enhancing the body's excretion of sodium (Na+) and water. This intense process of diuresis makes the medicine fundamentally useful for alleviating symptoms of fluid overload, particularly edema (swelling). For example, it's typically used to manage the retention of fluid associated with conditions like congestive heart failure. The primary role of the medication is to reduce fluid retention, helping to decrease swelling by causing the body to expel excess liquid. By actively reducing excess fluid volume, the medication helps restore a more normal fluid balance in the body.

Regulatory References

  1. MedlinePlus Drug Information on Bumetanide

What side effects are possible with Conart (DIURETICS)?

Possible Side Effects and Safety Information

The safety profile of Conart (Bumetanide), a potent loop diuretic, is strictly defined by its primary action of causing profound diuresis, which governs the majority of documented adverse reactions and safety constraints in regulatory labeling. The central safety concern is the high potential for volume depletion and resulting electrolyte imbalances.


Adverse Reaction Scope and Classification

Adverse effects are categorized by frequency and system-organ class. Common reactions documented in official sources include dehydration, hypotension (low blood pressure), dizziness, headache, and nausea. Due to its mechanism, the drug is also associated with metabolic changes such as hyperuricemia and hypokalemia (low potassium). Uncommon effects include diarrhea, vertigo, and urticaria.

Serious Adverse Reactions

Regulatory documents list serious adverse reactions that warrant attention. These include the risk of circulatory collapse and associated vascular thrombosis and embolism arising from excessive fluid loss. In patients with pre-existing hepatic cirrhosis, sudden electrolyte shifts may precipitate hepatic encephalopathy or coma. Severe cutaneous reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented. Ototoxicity, characterized by hearing disturbance or tinnitus, is a rare but documented risk, especially with rapid intravenous administration.

Population-Specific Safety Considerations

The official label provides targeted safety information for specific patient groups. Elderly patients are noted to be more susceptible to complications from volume depletion, including the risk of vascular complications. The medicine is contraindicated in patients with anuria (absence of urine formation), hepatic coma, or existing severe electrolyte depletion until the condition is corrected. For pediatric patients, the safety and effectiveness of the medicine are not established.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Conart, a potent loop diuretic, is officially documented to lead to severe physiological consequences due to excessive diuresis and profound water loss. The primary documented manifestations are volume depletion, severe dehydration, and critical electrolyte depletion, such as hypokalemia. Clinical signs reported in regulatory sources include weakness, dizziness, mental confusion, vomiting, and muscle cramps.

Life-Threatening Manifestations

Excessive dosing or too frequent administration can result in a significant reduction in blood volume leading to circulatory collapse and the possibility of vascular thrombosis and embolism. Regulatory labeling specifically notes that elderly patients are particularly susceptible to these severe vascular outcomes. For patients with hepatic cirrhosis, the rapid alteration of electrolyte balance may precipitate hepatic encephalopathy or coma.

Required Emergency Actions

Immediate medical attention is required upon the suspicion of an overdose. The official instruction is to seek immediate medical attention, or if the individual has collapsed, had a seizure, has trouble breathing, or can't be awakened, to immediately call emergency services. No specific antidote is known for this overdose. Treatment described in official documents consists of supportive measures, including restoring blood volume, maintaining blood pressure, and urgently correcting electrolyte disturbance, along with careful monitoring of serum electrolyte levels.

Therapeutic Uses of Conart (DIURETICS)

What Conart (DIURETICS) Treats: Main Uses and Benefits

The medicine is commonly used to help with symptomatic relief in situations where patients experience fluid retention associated with serious underlying conditions. The therapeutic domain for this medication generally includes edematous states associated with congestive heart failure, hepatic cirrhosis, and renal disease, including the nephrotic syndrome.

Relief from Symptom Clusters

This medication is commonly used to help with symptoms related to physical discomfort, such as those caused by edema and fluid accumulation. It is relevant for easing the swelling and pressure in the legs, ankles, and feet (peripheral edema), and to alleviate the discomfort caused by fluid accumulation in the abdomen (ascites). Conart is also relevant for managing acute symptoms, such as shortness of breath and respiratory distress, which are linked to organ-specific functional stress. By managing the excess fluid volume, the medicine supports general well-being and assists with maintaining functional stability during symptomatic periods in the context of these chronic conditions.


Quick Fact: Relief for Fluid Overload Symptoms

Property Description
Primary Symptoms Eased Peripheral edema, ascites, and fluid-induced shortness of breath
Targeted Conditions Congestive Heart Failure, Hepatic Cirrhosis, Renal Disease (Edematous States)
Key Benefit Provides supportive relief that helps ease the overall symptom load

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Conart (Bumetanide) is approved for use in adult patients for the treatment of fluid overload and edema. Its eligibility profile is strictly defined by regulatory authorities based on a patient's existing health status, including absolute prohibitions and conditions requiring restricted use.

Populations for Whom Use is Contraindicated Condition-Specific Restrictions
Patients with Anuria (absence of urine) Severe Hepatic Impairment (Use requires extreme caution due to risk of hepatic coma)
Patients in Hepatic Coma or Pre-coma states Severe Renal Impairment (Requires discontinuation if signs of worsening kidney function occur)
Patients with Severe Electrolyte Depletion Uncorrected Electrolyte Imbalances (e.g., Hypokalemia, Hyponatremia)
Patients with known Hypersensitivity to Bumetanide Diabetes Mellitus (Use requires caution as the drug may impair glucose tolerance)

Age-Related and Physiological Status Rules

  • Pediatric Patients (Under 18 Years): Safety and efficacy for chronic use are not established in official labeling. Use in neonates carries a risk of kernicterus.
  • Older Adults: Use is permitted; however, regulatory guidance recommends that dosage selection be cautious and typically started at the low end of the range.
  • Pregnancy: Use is not recommended unless the potential benefit outweighs the potential risk to the fetus (Pregnancy Category C).
  • Lactation: It is not known if the drug is excreted in human milk; a decision must be made to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Conart (Bumetanide) interactions primarily focuses on pharmacokinetic and pharmacodynamic outcomes that modify exposure or potentiate effects, as documented by government health authorities. Certain combinations carry specific constraints and risks.


Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class Officially Documented Interaction Pattern
Desmopressin Concurrent use is contraindicated due to the significantly increased risk of severe hyponatremia (low sodium levels).
Lithium Bumetanide reduces the renal clearance of Lithium, resulting in elevated blood-lithium levels and toxicity risk.
Aminoglycoside Antibiotics (e.g., Gentamicin) Co-administration increases the official risk of ototoxicity (inner ear damage), particularly with the injectable form.
Probenecid Reduces Bumetanide's natriuretic efficacy by inhibiting its renal tubular secretion.
NSAIDs (e.g., Indomethacin) May officially diminish the diuretic effect and increase the risk of nephrotoxicity.

Additional Constraints and Considerations

Other antihypertensive agents may result in the potentiation of hypotensive effects (low blood pressure) when co-administered. The risk of hypokalemia (low potassium levels) is additive when combined with other drugs that cause potassium loss. Patients with renal or hepatic impairment have a documented increased risk of toxicity and specific interaction severity with certain co-administered agents.

Mechanism of Action

How Conart (Torasemide) Works at the Biological Level

Conart (Torasemide) exerts its effect as an inhibitor by selectively targeting the Na^+/K^+/2Cl^- cotransporter ( NKCC2) protein. This cotransporter is embedded in the luminal membrane of cells within the thick ascending limb of the loop of Henle in the kidney nephron. Torasemide binds to the transporter, blocking the active reabsorption of Na^+, K^+, and Cl^- ions from the tubular fluid back into the bloodstream.

This molecular blockade initiates a cascade by increasing the concentration of ions retained in the tubular lumen, which creates an osmotic pressure gradient. This gradient impedes the passive reabsorption of water, leading to both natriuresis (salt excretion) and diuresis (water excretion). The resulting physiological consequence is the modulation of systemic fluid homeostasis through a decrease in extracellular fluid volume and a subsequent reduction in plasma volume, which results in a reduction of the volume of blood returning to the heart and contributes to a reduction in systemic blood pressure.

Dosage and Administration Information

Conart, which contains the loop diuretic Bumetanide, is administered through two primary official routes as determined by the clinical scenario. For long-term fluid management, the medicine is administered via oral tablets, which may be taken with or without food. When a rapid onset is required or oral absorption is impaired, the drug is administered via the parenteral route as an intravenous (IV) or intramuscular (IM) injection.


The standard oral administration schedule involves initiating with a dose of 0.5 mg to 2 mg, typically taken once daily in the morning. If the desired effect is not achieved, the dose may be repeated at 4- to 5-hour intervals for a maximum of two additional oral doses, with the total daily amount generally not exceeding 10 mg. Maintenance use may also follow an intermittent schedule, such as administration on alternate days or in short cycles. Due to the rapid effect of the medication, it is generally recommended to avoid taking a dose after 4 PM to avoid disruption of sleep.


Parenteral administration is initiated with 0.5 mg to 1 mg. When given intravenously, the injection must be administered slowly over 1 to 2 minutes. If a dose is missed, it should be taken as soon as remembered unless it is late in the day; doses should not be doubled. Dosage for vulnerable populations is specifically addressed: older adults are advised to initiate treatment cautiously at the lower end of the dosing range, and use in pediatric patients is not supported by established safety and efficacy data.

Recent Clinical Evidence

Diuretics, a cornerstone of therapy for fluid retention (edema) and hypertension, continue to be evaluated in clinical trials, particularly in the context of combination therapy and difficult-to-treat conditions like advanced heart failure.

Core Efficacy in Heart Failure (HF)

Loop diuretics, the most common type used for congestion in heart failure, are generally the primary treatment for relieving symptoms such as edema and shortness of breath. Although they are widely utilized, evidence from some small, older placebo-controlled trials suggests they may reduce the risk of death and worsening heart failure. However, data supporting their use to influence long-term clinical outcomes are often considered limited due to the small size and variability of many studies.

Combination Strategies and Resistance

Recent research has focused on managing diuretic resistance, where high doses of a loop diuretic are no longer sufficient to achieve adequate fluid loss. Studies have investigated the addition of a second diuretic, such as a thiazide, to the regimen. The goal of this sequential nephron blockade is to restore the body's response to the treatment.

  • Combination Outcomes: Trials comparing different combination strategies (e.g., adding an oral thiazide-like agent or intravenous thiazide) found that the addition of a second agent significantly improved diuretic efficacy and weight loss over 48 hours in patients with acute heart failure and resistance. No single combination strategy has been clearly shown to be superior for these immediate outcomes.

Considerations in Hypertension

For hypertension management, the efficacy and safety profiles of different thiazide-type diuretics are a focus of research. While many guidelines recommend thiazides as a first-line agent, studies have compared different drugs within this class, such as hydrochlorothiazide and chlorthalidone. Some analyses suggest that certain thiazide-like agents may be associated with better control of blood pressure and cardiovascular outcomes over the long term, though these benefits must be balanced against the potential for a higher risk of specific electrolyte imbalances, such as hypokalemia or hyponatremia, compared to other agents.

Key Studies & References

  1. Diuretics for hypertension: Hydrochlorothiazide or chlorthalidone?

Frequently Asked Questions (FAQ)

Common questions about Conart (DIURETICS) (FAQ)


Q: How quickly after taking Conart can a person expect to notice increased urination?

According to official product information, the primary effect of increased urination, known as diuresis, typically begins approximately 30 to 60 minutes after a person takes the oral tablet.


Q: How long does the primary diuretic effect of a dose of Conart typically last?

For usual doses of the oral tablet, the main diuretic effect is largely complete within 4 hours. The diuretic action is generally reported to last 4 to 6 hours after administration.


Q: Is it common for people taking Conart to experience dizziness or lightheadedness?

Dizziness is listed in regulatory sources as a common adverse reaction. Lightheadedness is also noted as a symptom associated with the fluid and electrolyte changes that the medicine may cause, which is a key safety concern.


Q: What are the general effects of Conart on the body’s sodium levels?

Regulatory information notes that Conart's mechanism of action is designed to increase salt excretion. This effect can lead to changes in electrolyte balance, including the potential for the development of low sodium levels (hyponatremia).


Q: What types of electrolyte imbalances are most commonly associated with Conart use?

The medicine is associated with changes in the balance of salts (electrolytes) in the body. Commonly reported effects include low levels of potassium (hypokalemia), chloride, and sodium.


Q: What are the reported effects of Conart on a person's daily fluid or water intake requirements?

Official information stresses the risk of volume depletion and dehydration due to the drug's potent action.


Q: Are muscle cramps a commonly reported side effect of Conart?

Muscle cramps are listed in regulatory documents as a commonly reported adverse reaction. These cramps are often associated with electrolyte changes, such as low potassium levels, which are a documented adverse reaction of the medicine.


Q: What research evidence exists about Conart's long-term effect on kidney function?

Regulatory labeling notes that any marked increase in markers of kidney function (such as blood urea nitrogen or creatinine) is a factor that may require therapeutic adjustment or discontinuation.


Q: What kind of liver conditions are described as making Conart unsuitable for use?

Conart is contraindicated in patients who are in a state of hepatic coma. Official product information notes that sudden electrolyte shifts can precipitate a worsening of the patient's condition known as hepatic encephalopathy.


Q: What is the reported relationship between Conart (DIURETICS) use and blood sugar levels?

The medicine is associated with metabolic changes in the body. According to adverse reaction documentation, Conart may cause an increase in the amount of sugar in the blood, a condition known as hyperglycemia.


Q: Why are diuretics like Conart commonly referred to as 'water pills'?

Conart is often referred to by the general public as a 'water pill' because of its main function. It works by increasing the flow of urine, which helps the body get rid of excess water and salt.


Q: What are the general signs of dehydration that people taking Conart should be aware of?

Patient information outlines several signs of dehydration. These may include feeling very thirsty, having a dry mouth, dizziness, and urinating less than usual or having dark-colored urine.


Q: What types of heart rhythm problems are sometimes associated with changes in electrolyte balance from Conart?

The drug's impact on electrolyte balance may cause changes to heart rhythm. Documented effects include a fast or irregular heartbeat or a disturbance in the normal rhythm, known as an arrhythmia.


Q: What are the documented safety classifications for Conart regarding use during breastfeeding?

Official sources indicate that it is unknown if the drug is excreted into breastmilk. Official sources state that the drug may potentially decrease milk flow or completely suppress lactation.


Q: Are there specific food types, such as potassium-rich foods, that are generally mentioned in relation to Conart?

Due to the drug's effect on potassium levels, patient information materials often mention potassium-rich foods (such as bananas or orange juice) in relation to managing this change.


Q: Are there any common herbal or dietary supplements that are generally described as interacting with diuretics like Conart?

General information regarding loop diuretics describes a need for caution with certain supplements. This includes herbs or supplements that also have a diuretic effect or those that may increase potassium loss (like licorice).


Q: Does the package insert for Conart describe potential effects on cholesterol levels?

Regulatory data, specifically postmarketing reports, includes a rare mention of abnormal blood cholesterol levels. This is not listed among the common adverse reactions.


Q: What general medical conditions mean a person cannot use a diuretic like Conart?

Official documents list several conditions that make the drug unsuitable for use. These contraindications include the complete absence of urine formation (anuria), hepatic coma, and pre-existing severe electrolyte depletion.


Q: Is a persistent headache a noted side effect that can occur with Conart?

Headache is explicitly listed in regulatory documents as a commonly reported adverse reaction.


Q: What is generally known about the difference between loop diuretics and thiazide diuretics, assuming Conart falls into one of these categories?

Conart is a loop diuretic. Official information differentiates these classes by noting that loop diuretics are commonly used in patients with moderate to severe chronic kidney disease or symptomatic heart failure.


Q: Does official information about Conart mention a change in hearing as a possible effect?

Hearing disturbance or tinnitus (ringing in the ears) is a rare, documented risk in the regulatory labeling, particularly when the intravenous form is administered rapidly or in patients with pre-existing kidney impairment.


Q: What is the general information on how Conart is processed and eliminated by the body?

Regulatory information indicates that the drug is primarily processed and eliminated from the body via renal tubular secretion in the kidney. This is the mechanism by which some other medicines may interfere with the drug’s efficacy.


Q: How does Conart compare to other diuretic classes in terms of its effect on potassium balance?

Like other medicines in the loop diuretic class, Conart is noted as being potassium-depleting. The need for potassium monitoring and potential supplementation is often addressed in patient information materials.


Q: What is the general information about Conart's safety profile during pregnancy?

Regulatory labeling states that the drug is to be used during pregnancy only when the potential benefit is determined to justify the potential risk to the fetus.


Q: Can Conart potentially affect a person's uric acid levels?

The medicine is known to decrease the excretion of uric acid by the body. This effect can result in hyperuricemia (high uric acid in the blood) and is listed in the adverse reactions section.

How should Conart (DIURETICS) be stored and disposed of?

Storage and Disposal Requirements for Conart (Bumetanide)

Official regulatory documents define specific conditions for storing and disposing of this diuretic medication. The primary storage mandate is to keep the product at Controlled Room Temperature, which is 20^circ to 25 C (68^circ to 77 F), while protecting it from light. The oral tablets must be kept in tight, light-resistant containers.

Storage Constraint Requirement
Temperature Controlled Room Temperature (20^circ to 25 C)
Container Tight, light-resistant
Child Safety KEEP OUT OF THE REACH OF CHILDREN

For disposal, the regulatory standard is to use a drug take-back program. Bumetanide should not be flushed down the toilet or poured down the sink. If a take-back program is unavailable, the medicine may be mixed with an undesirable substance and discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Conart (DIURETICS) found in:

A-Z Index: